Aims Angioplasty of lesions in small coronary arteries remains a significant problem because of the increased risk of restenosis. The aim of this study was to compare the efficacy of elective coronary stent placement and optimal balloon angioplasty in small vessel disease.
Introduction
Stent use has been growing continuously in advance of controlled clinical data, and today stents are a ubiquitous routine in interventional cardiology. However, coronary angioplasty of small vessel disease remains a significant problem because of the increased risk of restenosis [1] [2] [3] [4] [5] [6] [7] . Several studies have assessed the efficacy of elective stent placement for lesions in small coronary arteries with conflicting results [2] [3] [4] [5] [6] [7] . It is still controversial whether stents should be used only to treat suboptimal results or should be recommended as a primary therapy for small vessel disease.
Coronary stents allow a strategy of more aggressive balloon dilation and, therefore, the procedural results of balloon angioplasty have been greatly enhanced in the stent era. Recently, optimal balloon angioplasty with the limited use of provisional stenting was suggested to be a promising approach to improve the long-term outcome of primary angioplasty [8] [9] [10] [11] . However, to date there is little information regarding the efficacy of optimal balloon angioplasty for treatment of small vessel disease. We therefore conducted a prospective randomized trial comparing coronary stenting with optimal balloon angioplasty in these lesions.
Methods

Study patients
The study group consisted of patients with symptomatic ischaemic heart disease scheduled for elective coronary angioplasty. Inclusion criteria included a focal, de novo lesion (diameter stenosis >50%, lesion length <15 mm and reference artery diameter <3·0 mm) in a native coronary artery. The criteria for exclusion were contraindication to antiplatelet agents, ostial lesion, calcified lesion, total occlusion, infarct-related artery, left ventricular dysfunction (ejection fraction <40%) or inability to follow the protocol. Informed consent was given in accordance with the rules of the Institutional Ethics Committee which approved the study.
Randomization and angioplasty procedures
Eligible patients were randomly assigned to either balloon angioplasty (group I) or elective stent placement (group II) according to computer-generated randomization lists. Balloon angioplasty was performed with the use of moderately high pressure inflation (d10 atmospheres), and a goal of less than 30% residual diameter stenosis was set to obtain an optimal angiographic result. Crossover to stenting was performed when a residual diameter stenosis was more than 30%, or major dissection (types C-F by the NHLBI classification [12] ) occurred that could not be managed by repeated balloon angioplasty. For stent placement in group II, the 7-cell NIR stent mounted on a 2·5(2) mm balloon (Boston Scientific Corporation, Boston, USA) was used. After the pre-dilation, the stents were deployed by inflating the stent delivery balloon at a single high pressure (d10 atmospheres) and, if necessary, adjunct high pressure balloon dilation was performed to achieve angiographic optimization. During the procedure, patients received 10 000 U bolus of heparin with a repeat bolus of 5000 U to maintain the activated clotting time d300 s. We used aspirin and ticlopidine as antithrombotic regimen. Ticlopidine therapy (250 mg twice a day) was started at least 3 days before the stenting procedure and continued for 1 month. All patients received aspirin (200 mg a day) indefinitely.
Angiographic analysis
Two experienced angiographers unaware of the study goal analysed the angiographic results. The percentage of diameter stenosis, minimal lumen diameter and reference diameter using an on-line quantitative angiographic analysis system (ANCOR V2.0, Siemens, Germany) were measured before pre-dilation, after the stenting procedure and at follow-up. Angiographic measurements were made during diastole after intracoronary nitroglycerin administration using the guiding catheter for magnification calibration. Single matched views with the worst diameter stenosis were compared.
Follow-up and study end-points
All patients were requested to visit outpatient clinics at 1, 3 and 6 months and then every 4 months after stent placement. Coronary angiographic follow-up was performed at 6 months or earlier if they had recurrent symptoms. The primary end-point was angiographic evidence of restenosis, defined as diameter stenosis of more than 50% at follow-up. Secondary end-points included the incidence of clinical events such as death, myocardial infarction and target lesion revascularization. Myocardial infarction was diagnosed when cardiac enzyme (creatine kinase-MB) was elevated more than three-fold with chest pain d30 min or with the appearance of new electrocardiographic changes
Statistical analysis
A sample size of 120 was calculated to give the study a power of 80% to detect a reduction in restenosis rate from 50% to 30% with a P value of 0·05 [3] . Analysis was made on an intention-to-treat basis. Data were expressed as mean SD for continuous variables and as frequencies for the categorical variables. Continuous variables were compared by an unpaired Student's ttest, and categorical variables by a chi-squared test. A two-sided value of P<0·05 was required for statistical significance.
Results
From January 1997 to October 1998, 120 patients were enrolled in this study and randomized to group I (n=60 patients) or group II (n=60 patients). Twelve patients assigned to the group I crossed over to stent because of suboptimal results (n=8) or major dissection (n=4); stents were successfully placed in all patients assigned to group II.
Baseline characteristics
As shown in Table 1 , the baseline clinical and angiographic characteristics were not different between the two groups. In-hospital events including stent thrombosis, Q wave myocardial infarction, emergency bypass surgery or death did not occur in any patients.
Angiographic results
Quantitative angiographic data are shown in Table 2 , and cumulative frequency distribution curves of the minimal lumen diameter in Fig. 1 . At baseline, the minimal luminal diameter of the target vessel and the reference diameter were similar between the two groups ( Table 2) . Post-intervention minimal lumen diameter in group I was significantly smaller than that in group II (2·14 0·37 mm vs 2·42 0·36, P<0·05, respectively). However, at follow-up, the minimal lumen diameter was 1·52 0·48 mm in group I, and 1·33 0·68 mm in group II (P=ns). The acute gain was significantly larger in group II than in group I (1·85 0·55 mm vs 1·49 0·53, P<0·01, respectively) but late loss was also greater in group II than in group I (1·12 0·67 mm vs 0·63 0·48, P<0·01, respectively). Net gain was similar between the two groups (0·86 mm 0·66 vs 0·75 0·75, P=ns, respectively).
Angiographic restenosis and clinical outcomes
Angiographic follow-up was obtained in 111 of 120 patients (92·5% of those eligible), comprising 55 patients (91·8%) in group I, and 56 patients (93·3%) in group II, and the rates of angiographic restenosis were 30·9% in group I, and 35·7% in group II (P=ns). The remaining patients refused follow-up angiography, but they did not complain of any symptoms. Clinical outcomes are summarized in Table 3 . Clinical follow-up was available in all patients at 15·9 5·7 months. There was no death or myocardial infarction during the follow-up. Target lesion revascularization was performed in five patients with no difference between the two groups.
Discussion
In the present study, the results of optimal balloon angioplasty were comparable to those of primary stent placement for treatment of lesions in small coronary arteries. These results may provide the rationale for the use of balloon angioplasty as a primary therapy of these lesions, indicating that optimal balloon angioplasty with the limited use of stent placement may be a reasonable approach, rather than primary stenting strategy in the treatment of small vessel disease. 
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Coronary stenting is increasingly used to improve the clinical outcome as a primary angioplasty strategy. Without question, stents have contributed to progress in the field of interventional cardiology, although their use continues to have several limitations, such as high cost and in-stent restenosis. Previous studies have shown that coronary stent placement leads to a significant reduction in the incidence of clinical and angiographic restenosis compared with balloon angioplasty [13] [14] . However, these data may not be extrapolated to small vessel disease because patients in the study were a highly selected group with favourable lesion characteristics. Until now, few data are available about the efficacy of stent placement for lesions in small coronary arteries. Intravascular ultrasound study revealed that the degree of neointimal thickness is relatively constant and independent of stent size [15] . Therefore, stent placement into small vessels may certainly be associated with an increased risk of restenosis because late lumen loss may be greater in stents implanted into small vessels than those implanted into large vessels. Recently, the efficacy of balloon angioplasty has been much improved with the use of the aggressive balloon dilation technique to achieve the greatest lumen. The Optimal Coronary Balloon Angioplasty versus Stent (OCBAS) study established no significant differences between the two strategies in terms of angiographic restenosis and clinical events [8] . Our results are consistent with the OCBAS study, suggesting that this strategy may also be applicable for treatment of lesions in small coronary arteries.
Aggressive balloon dilation in small vessel disease may result in greater vascular injury, leading to high incidence of restenosis. However, it is not known whether the extent of vascular injury correlates with late restenosis in small vessel disease. In this study, high pressure balloon dilation (d10 atmospheres) can improve immediate angiographic results without evidence of an increased risk of restenosis. On the basis of our results, we strongly believe that stent placement in smaller arteries is too large an intervention to accept it as the primary modality of therapy. Further studies in larger patient populations are needed to resolve these issues.
Study limitations
Several potential limitations need to be addressed. First, this study is a small randomized trial, requiring large confirmatory studies. Second, stent design and metal thickness may be pertinent to outcomes in small vessels and, therefore, our findings may not be generalized to all types of stents. Third, angiographic restenosis rates are above 30%, but repeat revascularization events were 5% or less. This discrepancy may be explained by the absence of symptoms in most patients with angiographic restenosis. Finally, the results of this study may not be applicable to the entire range of small vessel disease because only patients with favourable lesion characteristics were included. Nevertheless, the present study indicates that optimal balloon angioplasty with provisional stenting may be considered as a primary Sixty patients were assigned to each group. No differences were observed between the two groups.
therapy in small vessel disease because the routine use of stents may not provide additional benefits for treatment of these lesions.
